Digging deep into “dirty” drugs – modulation of the methylation machinery.

Pleyer, L, Greil, R. Drug Metab Rev. 2015, 47(2): 252-279.

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

Melchardt, T, Hufnagl, C, Magnes, T, Weiss, L, Hutarew, G, Neureiter, D, Schlattau, A, Moser, G, Gaggl, A, Tränkenschuh, W, Greil, R, Egle, A. BMC Cancer. 2015, 15:725.

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.

Ganghammer, S, Hutterer, E, Hinterseer, E, Brachtl, G, Asslaber, D, Krenn, PW, Girbl, T, Berghammer, P, Geisberger, R, Egle, A, Zucchetto, A, Kruschinski, A, Gattei, V, Chigaev, A, Greil, R, Hartmann, TN. Oncotarget. 2015, 6(14): 12048-12060.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant, M, Pfeiler, G, Dubsky, PC, Hubalek, M, Greil, R, Jakesz, R, Wette, V, Balic, M, Haslbauer, F, Melbinger, E, Bjelic-Radisic, V, Artner-Matuschek, S, Fitzal, F, Marth, C, Sevelda, P, Mlineritsch, B, Steger, GG, Manfreda, D, Exner, R, Egle, D, Bergh, J, Kainberger, F, Talbot, S, Warner, D, Fesl, C, Singer, CF. LANCET. 2015, 386(9992): 433-443.

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.

Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, Hartmann TN, Greil R, Geisberger R. Br J Haematol. 2015 Aug,170(4):515-22. doi: 10.1111/bjh.13467. Epub 2015 May 4.

AIDing cancer treatment: Reducing AID activity via HSP90 inhibition.

Rebhandl, S, Geisberger, R. Eur J Immunol. 2015, 45(8): 2208-2211.

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Gnant, M, Sestak, I, Filipits, M, Dowsett, M, Balic, M, Lopez-Knowles, E, Greil, R, Dubsky, P, Stoeger, H, Rudas, M, Jakesz, R, Ferree, S, Cowens, JW, Nielsen, T, Schaper, C, Fesl, C, Cuzick, J. ANN ONCOL. 2015, 26(8): 1685-1691.

Basophil Reactivity as Biomarker in Immediate Drug Hypersensitivity Reactions-Potential and Limitations.

Steiner, M, Harrer, A, Himly, M. Front Pharmacol. 2016, 7: 171.

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

Greil, R, Obrtlíková, P, Smolej, L, Kozák, T, Steurer, M, Andel, J, Burgstaller, S, Mikušková, E, Gercheva, L, Nösslinger, T, Papajík, T, Ladická, M, Girschikofsky, M, Hrubiško, M, Jäger, U, Fridrik, M, Pecherstorfer, M, Králiková, E, Burcoveanu, C, Spasov, E, Petzer, A, Mihaylov, G, Raynov, J, Oexle, H, Zabernigg, A, Flochová, E, Palášthy, S, Stehlíková, O, Doubek, M, Altenhofer, P, Pleyer, L, Melchardt, T, Klingler, A, Mayer, J, Egle, A. Lancet Haematol. 2016, 3(7): e317-e329.

Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2,5) translocation.

Merkel, O, Hamacher, F, Griessl, R, Grabner, L, Schiefer, AI, Prutsch, N, Baer, C, Egger, G, Schlederer, M, Krenn, PW, Hartmann, TN, Simonitsch-Klupp, I, Plass, C, Staber, PB, Moriggl, R, Turner, SD, Greil, R, Kenner, L. J Pathol. 2015, 236(4): 44-56.